nutritional and metabolic diseases
Conditions
Interventions
After randomization, data will be collected from participants before and after the intervention, such as: demographic, anthropometric data, prognostic indexes, diagnoses, hematological and biochemical
Other
G07.203.300.456
Sponsors
Eliseuda Marinho da Silva
Hospital Universitário Lauro Wanderley
Eligibility
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Ages 18-90 years; after major abdominal surgery in ICU; contraindication or failure of enteral nutrition within 48 hours; use of parenteral nutrition for at least 7 days; no history of kidney or liver disease
Exclusion criteria
Exclusion criteria: Life expectancy greater than 7 days, ie palliative care; unstable hemodynamic state; chronic renal failure where dialysis is insufficient; previous history of severe 24-hour sepsis; liver failure with hepatic encephalopathy or portal hypertension; pre-existing endocrine disorders; continuous 24-hour propofol infusion; chronic maintenance of systemic steroid therapy; immunocompromise; pregnancy or lactation; severe brain injury; seizure disorder with anticonvulsant medication; metastatic cancer of lymphoma four; psychiatric history; family members unable to understand the nature and scope of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: Improvement of the inflammatory process is expected by supplementation of parenteral alanilglutamine dipeptide in critically ill patients following major abdominal surgery using laboratory examination (hematological and biochemical). Blood aliquots will be collected by qualified technicians from Lauro Wanderley University Hospital, packed in appropriate packaging and sent to the hospital's own laboratory, where they will follow the routine of methods, specific parameters: blood count determinations will be by flow cytometry by the Sysmex® XN analyzer. 1000 and the biochemical determinations performed by the Architec® C 8000 automated analyzer. The methods employed for lactic dehydrogenase will be lactatopyruvate (NADH) - UV optimized, urease urea, creatinine by Jaffé-Picrate alkaline, creatinine clearance by estimation of the Cockcroft-formula. Gault, ASL and AST by NADH (without pyridoxalphosphate), Alpha-phosphate by paranitrophenyl phosphate, GGT by modified Szasz, Total and direct bilirubin with dichlorophenyldiazonium salt, indirect bilirubin by calculating total bilirubin - direct total bilirubin cholesterol oxidase, HDL-C by homogeneous protein, LDL-C by Friedewald's formula, VLDL-C by calculation of total cholesterol - HDL-C and LDL-C, agglutination triglyceride, glucose by hexokinase, total proteins by biuride, bromocresol green albumin, calculus from Total protein and albumin, PCR and AGPA will be by agglutination of the serum sample via immunoturbidimetry. All observed at the beginning and after the intervention, always comparing with the control group. We will adopt a significance level of 5% to reject the null hypothesis.;Expected Outcome 2: Reduction in mortality from parenteral L alanyl Lglutamine supplementation in critically ill patients following major abdominal surgery is expected using the prognostic index for organ dysfunction, the Sequential Organ Failure Assessment (SOFA) recommended for patients. in intensive care units, w | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: A reduction in ICU and hospital stay (days) is expected in patients with supplementation of parenteral alanil glutamine dipeptide after major abdominal surgery using follow-up of the patient's hospitalization after intervention and comparing with the control group. We will adopt a significance level of 5% to reject the null hypothesis | — |
Countries
Brazil
Contacts
Public ContactEliseuda Silva
Hospital Universitário Lauro Wanderley
Outcome results
None listed